Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1Urogenital Neoplasms 1Stroke 1Lung Neoplasms 1Inflammation 1Depressive Disorder, Major 1Depression 1Colitis 1Cognitive Dysfunction 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

Therapeutics 4Psilocybin 3Surveys and Questionnaires 2Oxygen 2Methods 2Cognitive Behavioral Therapy 2enzalutamide 1darolutamide 1apalutamide 1abacavir 1Transurethral Resection of Prostate 1Transcranial Magnetic Stimulation 1Transcranial Direct Current Stimulation 1Thyroidectomy 1Standard of Care 1Saline Solution 1Psychotherapy 1Physical Examination 1Palliative Care 1Niacin 1Models, Nursing 1Mindfulness 1Methylphenidate 1Melatonin 1Injections 1Infliximab 1Hypnosis 1Ethanol 1Esketamine 1Early Detection of Cancer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Depression × Infliximab × Clear all
NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡